➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Harvard Business School
Medtronic
Colorcon
AstraZeneca

Last Updated: April 19, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for BGB-290

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug BGB-290?

BGB-290 is an investigational drug.

There have been 81 clinical trials for BGB-290. The most recent clinical trial was a Phase 1 trial, which was initiated on November 7th 2017.

The most common disease conditions in clinical trials are Lymphoma, Carcinoma, and Neoplasms. The leading clinical trial sponsors are BeiGene, BeiGene USA, Inc., and M.D. Anderson Cancer Center.

There are seven US patents protecting this investigational drug and eighty-six international patents.

Recent Clinical Trials for BGB-290
TitleSponsorPhase
Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody BGB-A1217 in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaBeiGenePhase 2
A Study of BGB-A1217 With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung CancerBeiGenePhase 3
A Study of BGB-11417 in Participants With Myeloid MalignanciesBeiGenePhase 1/Phase 2

See all BGB-290 clinical trials

Clinical Trial Summary for BGB-290

Top disease conditions for BGB-290
Top clinical trial sponsors for BGB-290

See all BGB-290 clinical trials

US Patents for BGB-290

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BGB-290   Start Trial Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors BEIGENE, LTD. (Grand Cayman, KY)   Start Trial
BGB-290   Start Trial Process for preparing a PARP inhibitor, crystalline forms, and uses thereof BEIGENE, LTD. (Grand Cayman, KY)   Start Trial
BGB-290   Start Trial Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors BEIGENE, LTD. (Grand Cayman, KY)   Start Trial
BGB-290   Start Trial Crystalline forms Array Biopharma Inc. (Boulder, CO)   Start Trial
BGB-290   Start Trial Cytokine conjugates for the treatment of proliferative and infectious diseases SYNTHORX, INC. (La Jolla, CA)   Start Trial
BGB-290   Start Trial Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors BeiGene, Ltd. (Grand Cayman, KY)   Start Trial
BGB-290   Start Trial Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors BeiGene, Ltd. (Grand Cayman, KY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for BGB-290

Drugname Country Document Number Estimated Expiration Related US Patent
BGB-290 Australia AU2011384858 2031-12-31   Start Trial
BGB-290 Brazil BR112014012628 2031-12-31   Start Trial
BGB-290 Canada CA2856309 2031-12-31   Start Trial
BGB-290 China CN103703004 2031-12-31   Start Trial
BGB-290 China CN106220635 2031-12-31   Start Trial
BGB-290 Cyprus CY1119804 2031-12-31   Start Trial
BGB-290 Denmark DK2797921 2031-12-31   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Harvard Business School
Medtronic
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.